{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:27:55Z","timestamp":1792798075030,"version":"4.5.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T00:00:00Z","timestamp":1716940800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T00:00:00Z","timestamp":1716940800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Microbiol Infect Dis"],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Amongst all etiologic hospital-acquired infection factors, <jats:italic>K. pneumoniae<\/jats:italic> strains producing New Delhi metallo-\u03b2-lactamase (KP-NDM) belong to pathogens with the most effective antibiotic resistance mechanisms. Clinical guidelines recommend using ceftazidime\/avibactam with aztreonam (CZA\u2009+\u2009AT) as the preferred option for NDM-producing Enterobacterales. However, the number of observations on such treatment regimen is limited. This retrospective study reports the clinical and microbiological outcomes of 23 patients with KP-NDM hospital-acquired infection treated with CZA\u2009+\u2009AT at a single center in Poland.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The isolates were derived from the urine, lungs, blood, peritoneal cavity, wounds, and peritonsillar abscess. In microbiological analysis, mass spectrometry for pathogen identification, polymerase chain reaction, or an immunochromatographic assay for detection of carbapenemase, as well as VITEK-2 system, broth microdilution, and microdilution in agar method for antimicrobial susceptibility tests were used, depending of the pathogens\u2019 nature. CZA was administered intravenously (IV) at 2.5\u00a0g every eight hours in patients with normal kidney function, and aztreonam was administered at 2\u00a0g every eight hours IV. Such dosage was modified when renal function was reduced.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>KP-NDM was eradicated in all cases. Four patients (17.4%) died: three of them had a neoplastic disease, and one - a COVID-19 infection.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The combination of CZA\u2009+\u2009AT is a safe and effective therapy for infections caused by KP-NDM, both at the clinical and microbiological levels. The synergistic action of all compounds resulted in a good agreement between the clinical efficacy of CZA\u2009+\u2009AT and the results of in vitro susceptibility testing.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10096-024-04859-y","type":"journal-article","created":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T16:02:27Z","timestamp":1716998547000},"page":"1579-1587","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Outcomes of 23 patients diagnosed with New Delhi metallo-beta-lactamase (NDM)-producing Klebsiella pneumoniae infection treated with ceftazidime\/avibactam and aztreonam at a single center in Poland"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6394-8451","authenticated-orcid":false,"given":"Aneta","family":"Guzek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-8355-0696","authenticated-orcid":false,"given":"Zbigniew","family":"Rybicki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6589-1460","authenticated-orcid":false,"given":"Dariusz","family":"Tomaszewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2101-5053","authenticated-orcid":false,"given":"Katarzyna","family":"Mackiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0514-2281","authenticated-orcid":false,"given":"Wies\u0142aw","family":"Piechota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6444-4124","authenticated-orcid":false,"given":"Andrzej","family":"Chcia\u0142owski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,29]]},"reference":[{"key":"4859_CR1","unstructured":"Centers for Diseases Control and Prevention (2019) Antibiotics resistance threats in the United States, 2019. [ https:\/\/www.cdc.gov\/drugresistance\/biggest-threats.html. Accessed March 8, 2024"},{"key":"4859_CR2","unstructured":"World Health Organization (2022) Global antimicrobial resistance and use surveillance system (GLASS) report 2022. [ https:\/\/www.who.int\/publications\/i\/item\/9789240062702. Accessed March 8, 2024"},{"issue":"3","key":"4859_CR3","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/S1473-3099(17)30753-3","volume":"18","author":"E Tacconelli","year":"2018","unstructured":"Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet DL, Pulcini C, Kahlmeter G, Kluytmans J, Carmeli Y, Ouellette M, Outterson K, Patel J, Cavaleri M, Cox EM, Houchens CR, Lindsay Grayson M, Hansen P, Singh N, Theuretzbacher U, Magrini N, WHO Pathogens Priority List Working Group (2018) Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis 18(3):318\u2013327. https:\/\/doi.org\/10.1016\/S1473-3099(17)30753-3","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"4859_CR4","doi-asserted-by":"publisher","first-page":"e0312122","DOI":"10.1128\/mbio.03121-22","volume":"14","author":"R Calderon-Gonzalez","year":"2023","unstructured":"Calderon-Gonzalez R, Lee A, Lopez-Campos G, Hancock SJ, Sa-Pessoa J, Dumigan A, McMullan R, Campbell EL, Bengoechea JA (2023) Modelling the gastrointestinal carriage of Klebsiella pneumoniae infections. mBio 14(1):e0312122. https:\/\/doi.org\/10.1128\/mbio.03121-22","journal-title":"mBio"},{"issue":"1","key":"4859_CR5","doi-asserted-by":"publisher","first-page":"7","DOI":"10.4067\/S0716-10182017000100001","volume":"34","author":"J Osorio","year":"2017","unstructured":"Osorio J, Barreto J, Samboni CF, C\u00e1ndelo LA, Alvarez LC, Benavidez S, T\u00e9llez RP, SantofimioD, Ramos JA, G\u00f3mez CA (2017) [Risk factors for acute kidney injury in patients treated with polymyxin B experience from 139 cases at a tertiary university hospital in Colombia]. Rev Chil Infectol 34(1):7\u201313. https:\/\/doi.org\/10.4067\/S0716-10182017000100001","journal-title":"Rev Chil Infectol"},{"issue":"5","key":"4859_CR6","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1093\/cid\/cir934","volume":"54","author":"DF Florescu","year":"2012","unstructured":"Florescu DF, Qiu F, McCartan MA, Mindru C, Fey PD, Kalil AC (2012) What is the efficacy and safety of colistin for the treatment of ventilator-associated pneumonia? A systematic review and meta-regression. Clin Infect Dis 54(5):670\u2013680. https:\/\/doi.org\/10.1093\/cid\/cir934","journal-title":"Clin Infect Dis"},{"issue":"6","key":"4859_CR7","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1007\/s15010-020-01520-6","volume":"48","author":"S Karakonstantis","year":"2020","unstructured":"Karakonstantis S, Kritsotakis EI, Gikas A (2020) Treatment options for K. pneumoniae, P. Aeruginosa and A. Baumannii co-resistant to carbapenems, aminoglycosides, polymyxins and tigecycline: an approach based on the mechanisms of resistance to carbapenems. Infection 48(6):835\u2013851. https:\/\/doi.org\/10.1007\/s15010-020-01520-6","journal-title":"Infection"},{"issue":"4","key":"4859_CR8","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.cmi.2021.11.025","volume":"28","author":"M Paul","year":"2022","unstructured":"Paul M, Carrara E, Retamar P, T\u00e4ngd\u00e9n T, Bitterman R, Bonomo A, de Waele J, Daikos GL, Akova M, Harbarth S, Pulcini C, Gernacho-Montero J, Seme K, Tumbarello M, Lindermann PC, Gandra S, Yu Y, Bassetti M, Mouton JW, Tacconelli E, Rodriguez-Ba\u00f1o J (2022) European Society of Clinical Microbiology and Infectious diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European Society of Intensive Care Medicine). Clin Microbiol Infect 28(4):521\u2013547. https:\/\/doi.org\/10.1016\/j.cmi.2021.11.025","journal-title":"Clin Microbiol Infect"},{"issue":"2","key":"4859_CR9","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1093\/cid\/ciac268","volume":"75","author":"PD Tamma","year":"2022","unstructured":"Tamma PD, Aitken SL, Bonomo RA, Mathers A, van Duin D, Clancy CJ (2022) Infectious Diseases Society of America 2022 Guidance on the treatment of extended-spectrum \u03b2-lactamase Producing enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat Resistance (DTR- P. aeruginosa). Clin Infect Dis 75(2):187\u2013212. https:\/\/doi.org\/10.1093\/cid\/ciac268","journal-title":"Clin Infect Dis"},{"issue":"11","key":"4859_CR10","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1093\/cid\/ciaa586","volume":"72","author":"M Falcone","year":"2021","unstructured":"Falcone M, Daikos GL, Tiseo G, Bassoulis D, Giordano C, Galfo V, Leonildi A, Tagliaferri E, Barnini S, Sani S, Farcomeni A, Ghiadoni L, Menichetti F (2021) Efficacy of Ceftazidime-Avibactam Plus Aztreonam in patients with bloodstream infections caused by Metallo-\u03b2-lactamase\u2013producing enterobacterales. Clin Infect Dis 72(11):1871\u20131878. https:\/\/doi.org\/10.1093\/cid\/ciaa586","journal-title":"Clin Infect Dis"},{"issue":"6","key":"4859_CR11","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1097\/QCO.0000000000000858","volume":"35","author":"S Windham","year":"2022","unstructured":"Windham S, Kollef MH (2022) How to use new antibiotics in the therapy of serious multidrug resistant gram-negative infections? Curr Opin Infect Dis 35(6):561\u2013567. https:\/\/doi.org\/10.1097\/QCO.0000000000000858","journal-title":"Curr Opin Infect Dis"},{"key":"4859_CR12","unstructured":"The European Committee on Antimicrobial Susceptibility Testing (EUCAST). Clinical breakpoints - breakpoints and guidance (2003) Available from: https:\/\/www.eucast.org\/clinical_breakpoints. Accessed March 8, 2024"},{"issue":"4","key":"4859_CR13","doi-asserted-by":"publisher","first-page":"445","DOI":"10.4103\/ijmm.IJMM_17_189","volume":"35","author":"S Laishram","year":"2017","unstructured":"Laishram S, Pragasam AK, Bakthavatchalam YD, Veeraraghavan B (2017) An update on Technical, interpretative and clinical relevance of Antimicrobial Synergy Testing methodologies. Indian J Med Microbiol 35(4):445\u2013468. https:\/\/doi.org\/10.4103\/ijmm.IJMM_17_189","journal-title":"Indian J Med Microbiol"},{"issue":"12","key":"4859_CR14","doi-asserted-by":"publisher","first-page":"4124","DOI":"10.1128\/JCM.01121-14","volume":"52","author":"CD Doern","year":"2014","unstructured":"Doern CD (2014) When does 2 plus 2 equal 5? A review of antimicrobial synergy testing. J Clin Microbiol 52(12):4124\u20134128. https:\/\/doi.org\/10.1128\/JCM.01121-14","journal-title":"J Clin Microbiol"},{"issue":"2","key":"4859_CR15","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1093\/jac\/dkx393","volume":"73","author":"A Jayol","year":"2018","unstructured":"Jayol A, Nordmann P, Poirel L, Dubois V (2018) Ceftazidime\/avibactam alone or in combination with aztreonam against colistin-resistant and carbapenemase-producing Klebsiella pneumoniae. J Antimicrob Chemother 73(2):542\u2013544. https:\/\/doi.org\/10.1093\/jac\/dkx393","journal-title":"J Antimicrob Chemother"},{"key":"4859_CR16","doi-asserted-by":"publisher","unstructured":"Sree RA, Gupta A, Gupta N, Veturi S, Reddy LS, Begum M, Shravani E, Challa HP, Reddy SS, Singamsetty A, Arumilli M, Reddy PN, Tirlangi PK (2003) Ceftazidime-Avibactam alone or in combination with Aztreonam versus Polymyxins in the management of carbapenem-resistant Klebsiella pneumoniae nosocomial infections (CAPRI study): a retrospective cohort study from South India. https:\/\/doi.org\/10.1007\/s15010-023-02094-9. Infection","DOI":"10.1007\/s15010-023-02094-9"},{"issue":"8","key":"4859_CR17","doi-asserted-by":"publisher","first-page":"e00779","DOI":"10.1128\/AAC.00779-19","volume":"63","author":"S Mikhail","year":"2019","unstructured":"Mikhail S, Singh NB, Kebriaei R, Rice SA, Stamper KC, Castanheira M, Rybak MJ (2019) Evaluation of the synergy of Ceftazidime-Avibactam in Combination with Meropenem, Amikacin, Aztreonam, Colistin, or Fosfomycin against Well-Characterized Multidrug-resistant Klebsiella pneumoniae and Pseudomonas aeruginosa. Antimicrob Agents Chemother 63(8):e00779\u2013e00719. https:\/\/doi.org\/10.1128\/AAC.00779-19","journal-title":"Antimicrob Agents Chemother"},{"key":"4859_CR18","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.jgar.2020.10.019","volume":"23","author":"P Bocanegra-Ibarias","year":"2020","unstructured":"Bocanegra-Ibarias P, Camacho-Ortiz A, Garza-Gonz\u00e1lez E, Flores-Trevi\u00f1o S, Kim H, Perez-Alba E (2020) Aztreonam plus Ceftazidime-Avibactam as treatment of NDM-1-producing Klebsiella pneumoniae bacteraemia in a neutropenic patient: last resort therapy? J Glob Antimicrob Resist 23:417\u2013419. https:\/\/doi.org\/10.1016\/j.jgar.2020.10.019","journal-title":"J Glob Antimicrob Resist"},{"issue":"1","key":"4859_CR19","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12941-023-00586-y","volume":"22","author":"L Zhang","year":"2023","unstructured":"Zhang L, Zhen S, Shen Y, Zhang T, Wang J, Li J, Lin Q, Xiao Z, Zheng Y, Jiang E, Han M, Wang J, Feng S (2023) Bloodstream infections due to Carbapenem-Resistant Enterobacteriaceae in hematological patients: assessment of risk factors for mortality and treatment options. Ann Clin Microbiol Antimicrob 22(1):41. https:\/\/doi.org\/10.1186\/s12941-023-00586-y","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"4859_CR20","unstructured":"The European Committee on Antimicrobial Susceptibility Testing (EUCAST). Cefiderocol susceptibility testing - an update (2023) Available from: https:\/\/www.eucast.org\/eucast_news\/news_singleview?tx_ttnews%5Btt_news%5D=554&cHash=46fef43d5bf84991a0af2d658deaf685. Accessed March 8, 2024"}],"container-title":["European Journal of Clinical Microbiology &amp; Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-024-04859-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10096-024-04859-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-024-04859-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,20]],"date-time":"2024-07-20T07:03:52Z","timestamp":1721459032000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10096-024-04859-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,29]]},"references-count":20,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["4859"],"URL":"https:\/\/doi.org\/10.1007\/s10096-024-04859-y","relation":{},"ISSN":["0934-9723","1435-4373"],"issn-type":[{"value":"0934-9723","type":"print"},{"value":"1435-4373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,29]]},"assertion":[{"value":"18 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee: Komisja Bioetyczna przy Wojskowej Izbie Lekarskiej w Warszawie (Approval No: KB 34\/ 2023). The Ethics Committee has waived the requirement for the investigators to obtain a signed informed consent form from the participants due to the observational nature of this study and the fact that there is no harm related to the study participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}